Downloads / CME Credit

Chair & Presenters

Daniel J. DeAngelo, MD, PhD
Chair and Presenter
Daniel J. DeAngelo, MD, PhD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Stephan A. Grupp, MD, PhD
Stephan A. Grupp, MD, PhD
University of Pennsylvania Perelman School of Medicine
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Charles Mullighan, MBBS, MD
Charles Mullighan, MBBS, MD
St. Jude Children’s Research Hospital
Memphis, Tennessee
Mark R. Litzow, MD
Mark R. Litzow, MD
Mayo Clinic
Rochester, Minnesota


Hyatt Regency Atlanta
Centennial III – Registration and Dinner
Centennial IV – Symposium
265 Peachtree Street, NE
Atlanta, GA 30303


6:00 PM   Registration and Dinner

6:30 PM   Welcome and Introduction: Defining the Future for ALL Treatment (Daniel J. DeAngelo, MD, PhD)

6:40 PM   The Intersection of MRD, Modern Prognostic Assessment, and Innovative Treatment in ALL (Charles Mullighan, MBBS, MD)

7:05 PM   The Arrival of Antibody Therapy in ALL: From Mechanisms to Foundational Data (Daniel J. DeAngelo, MD, PhD)

7:30 PM   A Look at the Future of Antibody-Based Combinations in ALL (Mark R. Litzow, MD)

7:55 PM    Exploring the Role of CAR T-Cell Therapy in a New ALL Landscape (Stephan A. Grupp, MD, PhD)

8:20 PM   Symposium Summary and Audience Q&A (Panel)

CME Information

Activity Description & Educational Objectives

New science is poised to change the way patients with acute lymphoblastic leukemia (ALL) are treated, particularly adult patients who have not consistently benefited from standard pediatric-derived chemotherapy protocols. Many factors have contributed to this imminent evolution in ALL care, including a modern understanding of minimal residual disease (MRD) as a prognostic factor and the rapid development of antibody- and immune-based treatments. Now, new scientific vistas are opening up in ALL based on the ability of new antibody technologies to enhance outcomes, as well as the potential effectiveness of chimeric antigen receptor (CAR) T-cell therapy; these exciting strategies are currently being assessed as components in novel combination regimens or as strategies to eradicate MRD.

PeerView’s live symposium will offer expert takes on these clinical trends and map out the future of ALL treatment by featuring analyses of the latest, updated clinical evidence on antibodies and CAR T-cell therapy. Our panel will also discuss the real-world experience with these innovative treatments, and assess a future where sequential and combination approaches may offer further improvements in patient care.

Upon completion of this activity, participants should be better able to:

Target Audience

This activity has been designed to meet the needs of hematologist-oncologists, hematologists, oncologists, advanced practice oncology nurses, and other healthcare professionals involved in the care of patients with ALL.

Requirements for Successful Completion

In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test and evaluation form.

Media: Symposium
Release and Expiration Date: Friday, December 8, 2017
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair and Presenter

Daniel J. DeAngelo, MD, PhD
Director of Clinical and Translational Research, Adult Leukemia
Institute Physician
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts


Stephan A. Grupp, MD, PhD
Novotny Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Director, Cellular Therapy and Transplant Section
Director, Cancer Immunotherapy Frontier Program
CCCR Director of Translational Research
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Mark R. Litzow, MD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Charles Mullighan, MBBS, MD
Member, Department of Pathology
Co-Leader, Hematological Malignancies Program
St. Jude Children’s Research Hospital
Memphis, Tennessee

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or Reference course # G6149-18-Z.


This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.


This activity is supported by an educational grant from Pfizer.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

We invite you to attend our other symposia while at the conference. For our Friday lunch symposia, register here:, or here: